

# Randomised Trial of Rectal Prolapse Surgery

<b>Submission date</b> 02/06/2003	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 20/11/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 02/05/2014	<b>Condition category</b> Urological and Genital Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr John Northover

**Contact details**  
St Mark's Hospital  
ICRF Colorectal Cancer Unit  
Watford Road  
Harrow  
United Kingdom  
HA1 3UJ

## Additional identifiers

## Study information

**Scientific Title**

**Acronym**  
PROSPER - PROlapse Surgery: PErineal or Rectopexy

**Study objectives**  
Full thickness rectal prolapse is a profoundly disabling condition, occurring mainly in parous women. The pathogenesis is ill understood; curative treatment is exclusively surgical. The prevalence of the condition is not known. Amongst the 50% (154) of senior surgical members of

the Association of Coloproctology responding to a questionnaire on the subject, the median number of prolapse operations performed annually was 6 (range 0-25). To make large-scale recruitment feasible, and to maximise the clinical relevance of the eventual findings, the National Rectal Prolapse Trial is designed to fit in with routine practice with a minimum of extra tests and investigations over those that would normally be required. About 1000 patients will be recruited into the trial over a 3 year period and followed for a minimum of 3 years.

A full thickness prolapse is the circumferential protrusion through the anus of all layers of the rectal wall. It is most common in young children and the elderly. The range of surgical methods available to correct the underlying anal sphincter or pelvic floor defects in a full thickness rectal prolapse poses the question about the choice of the best operation.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

Not provided at time of registration

### **Study design**

Randomised controlled trial

### **Primary study design**

Interventional

### **Study type(s)**

Treatment

### **Health condition(s) or problem(s) studied**

Full thickness rectal prolapse

### **Interventions**

Given the uncertainty as to the best method of intervention and the lack of informative randomised evidence, a two-stage randomised, controlled clinical trial is proposed. Eligibility for randomisation will be based on the 'uncertainty principle'; that is if a surgeon feels uncertain of the relative merits of the abdominal and perineal approach in a particular case, then randomisation can proceed between the abdominal and perineal approach. Alternatively, the abdominal or perineal approach can be chosen if considered to be clearly indicated.

Randomisation two is then undertaken: if the abdominal approach is elected or allocated at randomisation, then randomisation is between Suture Rectopexy and Resection Rectopexy, if perineal, randomisation is between Delorme's and Altemeier's operations.

### **Intervention Type**

Other

### **Phase**

Not Specified

### **Primary outcome(s)**

The primary measures of efficacy will be recurrence of rectal prolapse for randomisation 1 and bowel function for randomisation 2.

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

31/12/2007

## **Eligibility**

**Key inclusion criteria**

Patients eligible for this study will be those with full thickness rectal prolapse.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/01/2001

**Date of final enrolment**

31/12/2007

## **Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**St Mark's Hospital**

Harrow

United Kingdom

HA1 3UJ

# Sponsor information

## Organisation

Clinical Trials Unit University of Birmingham (UK)

## ROR

<https://ror.org/03angcq70>

# Funder(s)

## Funder type

Other

## Funder Name

The NHS R&D funded Clinical Trials Unit at the University of Birmingham and The BUPA Foundation (The Medical Research Charity)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/07/2013		Yes	No
<a href="#">Study website</a>	Study website	11/11/2025	11/11/2025	No	Yes